Lisata Therapeutics (NASDAQ:LSTA) & GeoVax Labs (NASDAQ:GOVX) Head to Head Contrast

GeoVax Labs (NASDAQ:GOVX) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Institutional & Insider Ownership

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 0.2% of GeoVax Labs shares are held by insiders. Comparatively, 9.6% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares GeoVax Labs and Lisata Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
Lisata Therapeutics	N/A	-116.08%	-90.55%

Risk & Volatility

GeoVax Labs has a beta of 3.69, suggesting that its share price is 269% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Earnings & Valuation

This table compares GeoVax Labs and Lisata Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49 million	0.87	-$21.47 million	($11.34)	-0.03
Lisata Therapeutics	$170,000.00	66.20	-$16.59 million	($1.64)	-0.76

Lisata Therapeutics has lower revenue, but higher earnings than GeoVax Labs. Lisata Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for GeoVax Labs and Lisata Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1	1	1	0	2.00
Lisata Therapeutics	1	2	0	0	1.67

GeoVax Labs presently has a consensus price target of $150.00, indicating a potential upside of 50,747.46%. Given GeoVax Labs’ stronger consensus rating and higher probable upside, equities analysts clearly believe GeoVax Labs is more favorable than Lisata Therapeutics.

Summary

Lisata Therapeutics beats GeoVax Labs on 7 of the 13 factors compared between the two stocks.

About GeoVax Labs

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

About Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.